Clinical trials: Age Related Maculopathy
Age-Related Macular Degeneration (ARMD)
Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration
Ranibizumab is derived from a murine monoclonal anti- vascular endothelial growth factor (VEGF) antibody and can penetrate through the many retinal cell layers following intravitreal injection.
- Trial name
- NCT00288561
- Testing
- ranibizumab
- Where
- Switzerland
- Sponsor
- Novartis
Neovascular Age-Related Macular Degeneration
ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration
The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of multiple doses of ARC1905 intravitreous injection when administered in combination with multiple doses of Lucentis® 0.5 mg/eye…
- Trial name
- NCT00709527
- Testing
- Avacincaptad Pegol
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Ophthotech Corporation
Wet Age-related Macular Degeneration (wAMD), Wet Age-related Macular Degeneration
To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)
The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of intravitreal injection of EXG202 in subjects with neovascular age-related Macular Degeneration (nAMD).
- Trial name
- NCT06888492
- Testing
- EXG202
- Where
- 2 sites in China
- Volunteers
- 8 people
- Sponsor
- Guangzhou Jiayin Biotech Ltd
Wet Macular Degeneration, Macular Degeneration
HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration
In this fifth year of anti-VEGF therapy for neovascular AMD, retinal physicians are collecting groups of patients who either do not or only partially respond to anti-VEGF therapy.
- Conditions
- Wet Macular Degeneration, Macular Degeneration, Retinal Pigment Epithelial Detachment
- Trial name
- HiPED (NCT01189019)
- Testing
- ranibizumab
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Anne Fung MD
Age-Related Macular Degeneration
Vascular Endothelial Growth Factor (VEGF) & LOC387715/HTRA1 Polymorphism in Polypoidal Choroidal Vasculopathy
This study is to investigate whether there is an association of the LOC387715/HTRA1 and vascular endothelial growth factor polymorphism with response to treatment with intravitreal ranibizumab injections for patients with…
- Trial name
- NCT01233128
- Where
- South Korea
- Volunteers
- 121 people
- Sponsor
- Kyungpook National University Hospital
Diabetic Retinopathy, Age Related Macular Degeneration
Retinal Care Data Repository
The Retinal Care Data Repository's primary objective is to make data available for Retinal Care to develop algorithms that improve the care of people with retinal diseases.
- Trial name
- NCT04794907
- Testing
- Observation
- Volunteers
- 1,000 people
- Sponsor
- Retinal Care Inc.
Neovascular Macular Degeneration
Pharmacokinetic Study of Intravitreal Aflibercept Injection in Eyes With Wet Age-related Macular Degeneration
The main goal is to study way that aflibercept injection behaves in the eye and in the body of patients with wet macular degeneration, in patients who have had previous vitreous removal surgery.
- Trial name
- DRAW (NCT02204683)
- Testing
- Aflibercept
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Nebraska
Macular Degeneration
Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)
There is a need to investigate the effectiveness of IVT aflibercept injection in routine clinical practice. The aim of this study is to collect 12-month real-world clinical data from treatment-naïve nAMD patients who started…
- Trial name
- REALE (NCT03411941)
- Testing
- Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
- Where
- Spain
- Volunteers
- 116 people
- Sponsor
- Bayer
Age-Related Macular Degeneration
The OMEGA Study: Use of Eye Drops to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration (Dry AMD)
The purpose of this trial is to compare the ability of two doses of OT-551 ophthalmic solution and drug-free solution to safely and effectively treat geographic atrophy associated with age-related macular degeneration.
- Trial name
- OMEGA (NCT00485394)
- Testing
- OT-551
- Where
- 17 sites in United States
- Volunteers
- 198 people
- Sponsor
- Othera Pharmaceuticals
Age-Related Macular Degeneration
An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration
This is an open-label, Phase 1 single-center study in approximately 40 subjects who have 1 eye with intermediate AMD, including a high-risk drusen without geographic atrophy (GA) subgroup and a noncentral GA subgroup.
- Trial name
- NCT02848313
- Testing
- Elamipretide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stealth BioTherapeutics Inc.
Age Related Macular Degeneration, Mild Cognitive Impairment (MCI)
Association Between Age-related Macular Degeneration and Cognitive Impairment Based on Exosome Proteomics
Aim: Preliminary serum exosomal proteomics of patients with dry age-related macular degeneration (AMD) and mild cognitive impairment (MCI) were analyzed using proteomics technology.
- Conditions
- Age Related Macular Degeneration, Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
- Trial name
- NCT06883461
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Shanghai 10th People's Hospital
Neovascular Age-Related Macular Degeneration
A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD
Phase 2b, multicenter, visual examiner-masked, randomized active-controlled, parallel-arm design study to evaluate the safety and duration of repeated IVT injections of 3 dose levels of GB-102 compared with aflibercept.
- Trial name
- ALTISSIMO (NCT03953079)
- Testing
- Drug: GB-102, Aflibercept
- Where
- 33 sites in United States
- Volunteers
- 56 people
- Sponsor
- Graybug Vision
Wet Age-related Macular Degeneration
The Study of Drug 601 in Patients With Wet Age-related Macular Degeneration (wAMD)
Multicenter study to evaluate the safety and tolerability in patients with wet Age-related macular degeneration (wAMD) treated with intravitreal recombinant humanized anti-VEGF monoclonal antibody
- Trial name
- NCT04468997
- Testing
- Drug 601
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Age-related Macular Degeneration
Dose Ranging Study of Carbidopa-levodopa
From 3 large patient databases, patients diagnosed with AMD who have never taken levodopa(L-DOPA) containing medications have a mean age of diagnosis at 71 years.
- Trial name
- NCT03023059
- Testing
- Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Snyder, Robert W., M.D., Ph.D., P.C.
Age Related Macular Degeneration
Safety Study of Use of Autologous Bone Marrow Derived Stem Cell in Treatment of Age Related Macular Degeneration
The purpose of this Phase I/II study is to investigate the safety and preliminary efficacy of unilateral intravitreally transplantation of adult bone marrow stem cells in subjects with geographic atrophy secondary to age-related…
- Trial name
- NCT02016508
- Testing
- autologous bone marrow derived stem cells
- Where
- Egypt
- Volunteers
- 1 people
- Sponsor
- Al-Azhar University
Wet Age Related Macular Degeneration, Diabetic Macular Edema
Time to Treatment Utilizing a Tele-Retinal Referral System for wAMD and DME: A Pilot Study
In this province, optometrists are often responsible for contacting the retinal specialists' office to arrange patients to be examined for suspected emergencies or more routine referrals related to the eye.
- Trial name
- NCT01899963
- Where
- Canada
- Volunteers
- 83 people
- Sponsor
- McMaster University
Age Related Macular Degeneration
Study for Recalcitrant Age Related Macular Degeneration
50 Patients with recalcitrant exudative age-related macular degeneration with a history of retinal or subretinal fluid after multiple intravitreal injections with ranibizumab 0.5mg and subsequently treated with ranibizumab 2.0mg…
- Trial name
- TURF (NCT01543568)
- Testing
- aflibercept 2.0 mg
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- David M. Brown, M.D.
Dry Age-related Macular Degeneration, Geographic Atrophy
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the investigational drug ACU-4429 in subjects with geographic atrophy.
- Trial name
- NCT01002950
- Testing
- ACU-4429
- Where
- 12 sites in United States
- Volunteers
- 72 people
- Sponsor
- Kubota Vision Inc.
Age - Related Macular Degeneration, Diabetic Retinopathy
A Comparison of the Checkup Vision Assessment System to Standard Vision Assessment Tools
The CLEAR study is testing the level of agreement between visual acuity and Amsler grid testing using a mobile vision testing application, Checkup Study, and standard in office methods.
- Conditions
- Age - Related Macular Degeneration, Diabetic Retinopathy, Metamorphopsia
- Trial name
- CLEAR (NCT02871817)
- Testing
- Paxos Checkup Study Mobile Medical Application
- Where
- 12 sites in United States
- Volunteers
- 143 people
- Sponsor
- Digisight Technologies, Inc.
Neovacular Age-related Macular Degeneration
UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD)
This study assessed systemic vascular endothelial growth factor (VEGF) level in patients with neovascular Age-related Macular Degeneration following treatment with Ranibizumab or Aflibercept.
- Trial name
- UNRAVEL (NCT01988662)
- Testing
- Neovascular Age-related Macular Degeneration
- Where
- 24 sites in Israel, Malaysia and 5 more
- Volunteers
- 205 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.